Introduction: Chronic obstructive pulmonary disease (COPD) is a lung disorder characterized by airway inflammation and irreversible airflow obstruction. Leptin is secreted by adipose tissue and known as a regulatory factor of food intake and energy homeostasis. Its receptor which provides its specific functions is presented in the lung. It was shown that increased serum leptin level is related with the local inflammatory response in COPD. Visfatin is a pro-inflammatory cytokine which plays a role in the regulation of inflammation. Visfatin is presented as a novel factor associated with systemic inflammation in COPD. The association between systemic or airway leptin or visfatin and COPD is remained controversial. For this reason, we aimed to evaluate serum levels of leptin and visfatin in patients with COPD. Materials&Methods: 27 COPD patients and 16 healthy controls were involved in our study. Blood samples were collected in tubes without EDTA. Serum levels of leptin and visfatin were measured by human ELISA assay kits. Statistical analyses were performed by SPSS 16.0 package program. Results: Serum level of leptin was detected as 100.18 ± 16.49 pg/ml in the COPD and 140.43 ± 17.21 pg/ml in the control group. Serum level of visfatin was found as 0.08 ± 0.01 pg/ml in the COPD and 0.06 ± 0.01 pg/ml in the control group. Serum levels of leptin and visfatin were not significantly changed in the COPD group compared to control (respectively; p = 0.053, p = 0.062). Conclusion: According to our results we can conclude that leptin and visfatin may be controlled physiologically under COPD conditions. On the other hand serum level of leptin and visfatinin COPD patients may be related with genetic polymorphic focus.